This study showed that TAT targeting PD-L1 in a human melanoma xenograft model was associated with efficient anti-tumor response, as demonstrated by significant delay in tumor growth and improved survival with minimal hematologic toxicity. The gene discussed is CD274; the disease is melanoma.